[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Affiliated Hospital of Hangzhou Normal University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":169},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,75,96,119,144],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100611485","a-community-based-prospective-cohort-study-on-metabolic-dysfunction-associated-fatty-liver-disease-in-older-adults-from-metabolic-trajectories-to-extrahepatic-outcomes-100611485",false,"NCT07241195","A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes","Study on the Construction of Disease Cohort for Fatty Liver in the Elderly and Its Prevention and Treatment Strategies","COMET cohort","Inclusion Criteria:\n\n* ① Elderly people aged ≥65 years among permanent residents (living for more than 5 years) in the survey area;\n\n  * Imaging diagnosis (ultrasound or FibroScan\u002FFibroTouch) of fatty liver; -③ Voluntary participation in this study and signing an informed consent form.\n\nExclusion Criteria:\n\n* ①Major disability, mental illness, major wasting disease, severe cardiac, pulmonary and renal insufficiency;\n\n  * Patients with combined primary liver cancer or other types of cancer; -③Patients who have received liver transplant or other organ transplants.",true,"ALL","65 Years","100 Years",{"count":22,"type":23},20000,"ESTIMATED","2 Years","OBSERVATIONAL","To establish a cohort of elderly fatty liver disease based on the community medical examination population. Through the large-scale cohort study, the risk factors affecting fatty liver in the elderly will be explored in depth from the aspects of lifestyle, environment and genetics, the development pattern and mechanism of fatty liver in the elderly will be analysed, and the health risk assessment system and Chinese standard for fatty liver in the elderly covering cardiovascular risk, risk of hepatic fibrosis and risk of sarcopenia will be established, so as to provide the scientific basis for the precise intervention of fatty liver in the elderly in China.",[28,29,30],"NAFLD and NASH","NAFLD( Non-alcoholic Fatty Liver Disease )","NAFLD Cirrhosis","RECRUITING","2026-05-28",{"date":34,"type":35},"2026-06-01","ACTUAL",{"date":37,"type":35},"2026-03-12",{"date":39,"type":23},"2030-12-31",{"name":41,"class":42},"The Affiliated Hospital of Hangzhou Normal University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":18,"minAge":52,"maxAge":19,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":43},"100623666","personalized-transcranial-magnetic-stimulation-tms-for-metabolic-dysfunction-and-alcohol-related-liver-disease-100623666","NCT07399600","Personalized Transcranial Magnetic Stimulation (TMS) for Metabolic Dysfunction and Alcohol-Related Liver Disease","Personalized Transcranial Magnetic Stimulation for Metabolic Dysfunction and Alcohol-Related Liver Disease (MetALD): A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial","P-TMS MetALD","Inclusion Criteria:\n\n* Participants are able to understand the study protocol, requirements, and restrictions, are fully informed of potential adverse events, are willing to comply with follow-up visits, and voluntarily sign the informed consent form before enrollment.\n* Meet the diagnostic criteria for MASLD according to the Guidelines for the Prevention and Treatment of Metabolic (Non-Alcoholic) Fatty Liver Disease (2024 Edition), and fulfill the European definition of MetALD with moderate alcohol consumption (20-50 g\u002Fday for women; 30-60 g\u002Fday for men).\n* Age between 18 and 65 years.\n* Body mass index (BMI) \\> 24 kg\u002Fm².\n* No history of alcohol abuse.\n\nExclusion Criteria:\n\n* Contraindications to magnetic resonance imaging (MRI) or transcranial magnetic stimulation (TMS).\n* Mild cognitive impairment, defined as Montreal Cognitive Assessment (MoCA) score \\\u003C 25.\n* Severe comorbid somatic diseases or neurological disorders.\n* History of psychiatric disorders, or current use of antipsychotic medications.\n* Pregnant or breastfeeding women, or those planning pregnancy.\n* Previous TMS treatment within the last 3 months.","18 Years",{"count":54,"type":23},105,"INTERVENTIONAL",[57],"NA","The goal of this clinical trial is to learn if repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive brain stimulation technique, works to treat Metabolic dysfunction-associated and alcohol-associated liver disease (MetALD). The main questions it aims to answer are:\n\n* Can rTMS effectively treat MetALD?\n* Is an individualized, precision-targeted rTMS approach more effective than the standard rTMS method?\n* What changes in brain activity are associated with the treatment?\n\nResearchers will compare three different types of stimulation:\n\n* Group A: Individualized rTMS targeting a deep brain reward area (the Nucleus Accumbens) based on each participant's brain scan (fMRI).\n* Group B: Standard rTMS applied using the traditional \"5 cm\" rule for positioning.\n* Group C: Sham (placebo) rTMS, which mimics the procedure but delivers no significant magnetic stimulation.\n\nParticipants will:\n\n* Be randomly assigned to one of the three groups (A, B, or C).\n* Undergo an MRI brain scan before starting treatment.\n* Receive a total of 20 rTMS sessions, completing at least 4 sessions per week.\n* Have additional MRI scans and clinical assessments halfway through and immediately after the treatment course.\n* Attend follow-up visits at 1, 3, and 6 months after treatment completion to assess long-term effects.",[60,61,62],"Liver Diseases, Alcoholic","Fatty Liver","Metabolic Syndrome",[60,61,62,64,65],"Transcranial Magnetic Stimulation","Randomized Controlled Trial","NOT_YET_RECRUITING","2026-02-03",{"date":69,"type":35},"2026-02-10",{"date":71,"type":23},"2026-02-01",{"date":73,"type":23},"2027-12-31",{"name":41,"class":42},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":18,"minAge":52,"maxAge":19,"enrollmentInfo":82,"targetDuration":4,"studyType":55,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":43},"100610892","a-multicenter-randomized-crossover-clinical-trial-study-of-digital-intelligence-software-in-patients-with-mafld-100610892","NCT07233486","A Multicenter, Randomized, Crossover Clinical Trial Study of Digital Intelligence Software in Patients With MAFLD","DISMA","Inclusion Criteria\n\n1. Adult patients aged 18-65 years with a BMI of 24-35 kg\u002Fm².\n2. Confirmed diagnosis of Metabolic-associated Fatty Liver Disease (MAFLD), defined by a FibroScan® result \\> 248 dB\u002Fm or an MRI-PDFF \\> 5%.\n3. Willing and able to provide written informed consent and comply with the study protocol, including the use of a compatible smartphone for digital health components.\n4. If treated for Type 2 Diabetes Mellitus (T2DM), must be on a stable medication regimen for at least 3 months prior to baseline (Day 0), with the expectation to maintain stability throughout the study barring medical necessity.\n5. If taking medications with potential NASH-remitting effects (e.g., vitamin E, thiazolidinediones), must be on a stable dose for at least 3 months prior to Day 0.\n\nExclusion Criteria\n\n1. Subjects were excluded from participation if they met any of the following criteria, based on the most recent pre-randomization assessments:\n2. Evidence of cirrhosis, defined as histological stage F4 or its clinical equivalent.\n3. History of heavy alcohol consumption (\\>30 g\u002Fday for males, \\>20 g\u002Fday for females) for more than 3 consecutive months within one year prior to screening.\n4. Prior or planned solid organ transplantation (excluding corneal transplants).\n5. Planned bariatric surgery. A history of bariatric surgery was permitted only if weight had been stable (variation \\\u003C10%) for at least 3 months prior to screening.\n6. Presence of other chronic liver diseases, including:\n7. Hepatitis B surface antigen (HBsAg) positivity.\n8. Hepatitis C virus (HCV) RNA positivity.\n9. Primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis, or overlap syndromes.\n10. Wilson's disease, alpha-1 antitrypsin deficiency (ZZ phenotype), or hereditary hemochromatosis.\n11. History of Type 1 Diabetes Mellitus. Uncontrolled Type 2 Diabetes Mellitus, defined as HbA1c \\>9% or current insulin therapy.\n12. History of hepatic decompensation events (e.g., ascites, hepatic encephalopathy, variceal hemorrhage).\n13. Any of the following laboratory abnormalities at screening:\n14. Platelet count \\\u003C 150,000\u002Fmm³\n15. Albumin \\\u003C 3.0 g\u002FdL\n16. International Normalized Ratio (INR) \\> 1.3\n17. Alkaline Phosphatase (ALP) \\> 2 × Upper Limit of Normal (ULN)\n18. Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \\> 5 × ULN\n19. Total Bilirubin \\> 1.3 × ULN (except in cases of documented Gilbert's syndrome)\n20. Estimated Glomerular Filtration Rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m²\n21. Hemoglobin \\\u003C 10 g\u002FdL\n22. Uncontrolled thyroid dysfunction, defined as a thyroid-stimulating hormone (TSH) level \\\u003C 0.1 or \\> 10 µIU\u002FmL at screening.\n23. Documented HIV-1 or HIV-2 infection.\n24. Known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.\n25. Significant cardiovascular history, including myocardial infarction, unstable angina, heart failure, uncontrolled arrhythmia, coronary artery bypass graft, or percutaneous coronary intervention within one year prior to screening.\n26. Diagnosis of malignancy within the past 2 years (except for adequately treated basal cell carcinoma or cutaneous squamous cell carcinoma).\n27. Severe co-morbid respiratory, cardiac, cerebrovascular, hepatic, or renal conditions that, in the investigator's judgment, would preclude safe participation in a diet and exercise intervention.\n28. Active, severe infection requiring parenteral antimicrobial therapy within 30 days of screening.\n29. Major surgery within 30 days prior to screening.\n30. Chronic use of medications known to promote hepatic steatosis (e.g., systemic corticosteroids, amiodarone, methotrexate, tamoxifen, valproic acid) within 3 months of screening. Short-term, low-dose corticosteroid use was permissible.\n31. Current or planned treatment with radiation therapy, cytotoxic chemotherapy, or immunomodulatory agents (e.g., interleukins, interferons).\n32. Treatment with any investigational agent within 6 months prior to screening, or prior participation in a clinical trial for NASH\u002FMAFLD within 6 months.\n\nPregnancy or lactation.\n\n1.Any other condition or circumstance that, in the opinion of the Investigator, would compromise patient safety or the validity of the study data.",{"count":83,"type":23},2000,[57],"Cirrhosis associated with metabolic associated fatty liver disease (MAFLD) can lead to a series of adverse outcomes in and outside the liver, but there is no approved treatment so far. In recent years, the prevalence of MAFLD-related cirrhosis in our country is increasing rapidly, but its clinical, pathological characteristics and natural prognosis are not clear, and there is a lack of standardized and effective prevention and treatment strategies.Through\"Digital Intelligence software\" to assist clinicians in MAFLD patients with remote data intervention, lifestyle intervention guidance and follow-up management, to evaluate the efficacy and safety of the intervention software on body weight and blood glucose in patients with MAFLD.",[87],"MAFLD","2025-11-17",{"date":90,"type":35},"2025-11-18",{"date":92,"type":35},"2024-08-01",{"date":94,"type":23},"2028-08-30",{"name":41,"class":42},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":43},"100592258","chinese-cardiologists-knowledgepractices-on-flu-vaccine-for-chronic-coronary-syndrome-100592258","NCT06991088","Chinese Cardiologists' Knowledge\u002FPractices on Flu Vaccine for Chronic Coronary Syndrome","Research on the Cognition and Practices of Chinese Cardiologists Regarding Influenza Vaccination for Patients With Chronic Coronary Syndrome","Inclusion Criteria:\n\nCardiologists (licensed practitioners) with specialized knowledge of the association between influenza vaccination and cardiovascular diseases.\n\nExclusion Criteria:\n\n* Physicians from non-cardiology specialties (e.g., surgery, general internal medicine \\[including respiratory and gastroenterology departments\\], emergency medicine).\n* Physicians unable to complete the questionnaire survey.",{"count":104,"type":23},5000,"This long-term single-center cross-sectional study evaluates physicians' knowledge of influenza vaccination in CCS patients through collected feedback, while identifying knowledge gaps and misconceptions regarding vaccination. By analyzing factors influencing physicians' recommendation practices, it provides evidence to guide future educational and policy interventions. Ultimately, the study aims to enhance cardiologists' vaccination awareness, thereby optimizing CCS patient management and reducing influenza-associated complications and mortality.",[107],"Chinese Cardiologists",[109,107,110],"Chronic Coronary Syndrome","Knowledge Survey","2025-05-29",{"date":113,"type":35},"2025-06-04",{"date":115,"type":23},"2025-06",{"date":117,"type":23},"2027-05",{"name":41,"class":42},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":17,"sex":18,"minAge":52,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":43},"100567060","acute-effects-of-meteorological-factors-and-air-pollution-on-cardiovascular-health-100567060","NCT06663267","Acute Effects of Meteorological Factors and Air Pollution on Cardiovascular Health","Inclusion Criteria:\n\n·Relevant records in the physical examination database shall be ≥3 times\n\n·≥18 years old\n\nExclusion Criteria:\n\n* Relevant records in the physical examination database shall be ≥３times\n* Serious heart and lung diseases\n* Malignant tumors\n* Serious mental illness in the past","75 Years",{"count":127,"type":23},350000,"The goal of this observational study is to analyze the acute effects of meteorological factors and air pollution on cardiovascular system. The main question it aims to answer is:\n\n1. How do meteorological factors and air pollution affect cardiovascular system?\n2. What is the interaction between meteorological factors and air pollution on cardiovascular system?\n\nParticipants will:\n\n1. Provide their health data obtained in physical examination, including but not limited to blood pressure, blood routine, urine routine and B-ultrasound.\n2. agree that the research team will use their personal identification number, gender, age, education level and other information for statistical analysis of the data.",[130,131],"Cardiovascular System","Health",[130,133,134,135],"Air Pollution Exposure","Acute effect","Weather","2024-10-26",{"date":138,"type":35},"2024-10-29",{"date":140,"type":23},"2024-11",{"date":142,"type":23},"2028-05",{"name":41,"class":42},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":18,"minAge":52,"maxAge":125,"enrollmentInfo":152,"targetDuration":4,"studyType":55,"phases":154,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":166,"leadSponsor":168,"locationsCount":4},"100526503","study-on-mafld-related-cirrhosis-prevention-and-treatment-strategies-100526503","NCT06135584","Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies","Prospective Cohort Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies","SMART","Inclusion Criteria:\n\n1. Age 18-75 years old, gender and ethnicity are not limited;\n2. Meet the diagnostic criteria for MAFLD;\n3. F0-F4 stage of liver fibrosis confirmed by liver biopsy within 24 weeks;\n4. Be willing to sign informed consent.\n\nExclusion Criteria:\n\n1. Cirrhosis due to any chronic liver disease other than MAFLD (including but not limited to alcohol or drug abuse, medications, chronic hepatitis B or C, autoimmune, hemochromatosis, Wilson's disease, alpha1-antitrypsin deficiency);\n2. Any clinical evidence or history of peritonitis, varicose bleeding, or spontaneous encephalopathy;\n3. According to the investigators' assessment, a history of heavy drinking for more than 3 months continuously within the previous year was selected. (Note: Heavy drinking was defined as more than 20 g per day on average for female subjects and more than 30 g per day for male subjects).\n4. Use of NAFLD-related medication history (amiodarone, methotrexate, systemic glucocorticoids, tetracycline, tamoxifen, larger than hormone replacement doses of estrogen, anabolic steroids, valproic acid, and other known hepatotoxins) for more than 2 weeks within the year prior to screening.",{"count":153,"type":23},1000,[57],"To establish a prospective, multicenter, biopsie-confirmed clinical cohort of MAFLD-related cirrhosis (F3-F4) in China, and analyze the clinical, histopathological features and natural outcomes of MAFLD-associated liver fibrosis\u002Fcirrhosis in China. And than to conducted a real-world study of different strategies of Chinese characteristics for the prevention and treatment of MAFLD-related cirrhosis to evaluate the efficacy and safety of the strategies.",[157,158],"Metabolic Dysfunction-associated Fatty Liver Disease","Cirrhosis",[160,161],"Treatment Strategies","Multicenter Real-World Study","2023-11-15",{"date":164,"type":35},"2023-11-18",{"date":164,"type":23},{"date":167,"type":23},"2026-12-31",{"name":41,"class":42},""]